Suo Y

No ORCID on file · 2 papers in corpus · active 2024-2025
2025
Knockdown of TOP2A reverses cisplatin resistance in ovarian cancer by inhibiting EMT via ferroptosis mediated by the TP53/GPX4/SLC7A11 axis.
Frontiers in immunology ·doi:10.3389/fimmu.2025.1675373

IntroductionCisplatin resistance is a major challenge in ovarian cancer therapy, particularly for high-grade serous ovarian cancer (HGSOC). DNA topoisomerase IIα (TOP2A) relates to cancer drug resistance, yet its role and molecular mechanis…

2024
Application of 3D reconstruction and 3D printing technology in advanced ovarian cancer surgery: a retrospective study.
Frontiers in oncology ·doi:10.3389/fonc.2024.1432970

BackgroundsAdvanced ovarian cancer is frequently accompanied by extensive peritoneal metastasis, complicating surgical interventions. This study aims to explore the application of 3D reconstruction and 3D printing technology in the treatmen…